DrugPatentWatch Database Preview

Daiichi Sankyo Inc Company Profile

« Back to Dashboard

What is the competitive landscape for DAIICHI SANKYO INC, and when can generic versions of DAIICHI SANKYO INC drugs launch?

DAIICHI SANKYO INC has four approved drugs.

There are three US patents protecting DAIICHI SANKYO INC drugs.

There are one hundred and six patent family members on DAIICHI SANKYO INC drugs in thirty-one countries and nine supplementary protection certificates in seven countries.

Summary for Daiichi Sankyo Inc

International Patents:	106
US Patents:	3
Tradenames:	4
Ingredients:	4
NDAs:	4
Patent Litigation for Daiichi Sankyo Inc:	See patent lawsuits for Daiichi Sankyo Inc

Drugs and US Patents for Daiichi Sankyo Inc

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Daiichi Sankyo Inc	MORPHABOND ER	morphine sulfate	TABLET, EXTENDED RELEASE;ORAL	206544-003	Oct 2, 2015		RX	Yes	No
Daiichi Sankyo Inc	MORPHABOND ER	morphine sulfate	TABLET, EXTENDED RELEASE;ORAL	206544-001	Oct 2, 2015		RX	Yes	No
Daiichi Sankyo Inc	EVOXAC	cevimeline hydrochloride	CAPSULE;ORAL	020989-002	Jan 11, 2000	AB	RX	Yes	Yes
Daiichi Sankyo Inc	SAVAYSA	edoxaban tosylate	TABLET;ORAL	206316-002	Jan 8, 2015		RX	Yes	No	7,365,205			Y

Expired US Patents for Daiichi Sankyo Inc

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Daiichi Sankyo Inc	EVOXAC	cevimeline hydrochloride	CAPSULE;ORAL	020989-002	Jan 11, 2000	4,855,290
Daiichi Sankyo Inc	EVOXAC	cevimeline hydrochloride	CAPSULE;ORAL	020989-002	Jan 11, 2000	5,580,880
Daiichi Sankyo Inc	EVOXAC	cevimeline hydrochloride	CAPSULE;ORAL	020989-002	Jan 11, 2000	5,340,821

Paragraph IV (Patent) Challenges for DAIICHI SANKYO INC drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Capsules	30 mg		2009-02-27

Non-Orange Book US Patents for Daiichi Sankyo Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
7,342,014	Diamine derivatives
9,707,296	Pharmaceutical composition

International Patents for Daiichi Sankyo Inc Drugs

Country	Document Number	Estimated Expiration
Russian Federation	2004106625
Poland	367532
Canada	2680039
Norway	2015022

Supplementary Protection Certificates for Daiichi Sankyo Inc Drugs

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2015000077	Germany		PRODUCT NAME: EDOXABAN, DESSEN SALZ, DESSEN SOLVAT, ODER DESSEN N-OXID, INSBESONDERE EDOXABANTOSILAT; REGISTRATION NO/DATE: EU/1/15/993/001-028 20150619
835	Luxembourg		PRODUCT NAME: EDOXABAN, UN DE SES SELS, UN DE SES SOLVATES OU UN N-OXYDE DE CELUI-CI, EN PARTICULIER UN TOSYLATE D EDOXABAN. FIRST REGISTRATION: 20150619
292	Luxembourg		PRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE
2015 00052	Denmark		PRODUCT NAME: EDOXABAN, OR A SALT THEREOF, A SOLVATE THEREOF, OR AN N-OXIDE THEREOF, IN PARTICULAR EDOXABAN TOSYLATE; REG. NO/DATE: EU/1/15/993/001-028 20150623

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Daiichi
• Daiichi Sankyo
• Daiichi Sankyo Inc